These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 2506219

  • 1. Delayed occurrence of an LH surge after HCG administration during ovarian stimulation with gonadotrophins: effect of LHRH treatment.
    Rojas FJ, Moretti-Rojas I, Balmaceda JP, Asch RH.
    Hum Reprod; 1989 Aug; 4(6):643-6. PubMed ID: 2506219
    [Abstract] [Full Text] [Related]

  • 2. Assessment of serum luteinizing hormone during ovarian stimulation with gonadotrophins.
    Rojas FJ, Moretti-Rojas I, Balmaceda JP, Asch RH.
    Hum Reprod; 1988 Feb; 3(2):207-11. PubMed ID: 3128573
    [Abstract] [Full Text] [Related]

  • 3. Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization.
    Droesch K, Muasher SJ, Brzyski RG, Jones GS, Simonetti S, Liu HC, Rosenwaks Z.
    Fertil Steril; 1989 Feb; 51(2):292-7. PubMed ID: 2492234
    [Abstract] [Full Text] [Related]

  • 4. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D, Alper MM, Oskowitz SP, Lobel SM, Mortola JF, Pavlou SN.
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [Abstract] [Full Text] [Related]

  • 5. Spontaneous luteinizing hormone surges can be reliably prevented by the timely administration of a gonadotrophin releasing hormone antagonist (Nal-Glu) during the late follicular phase.
    Frydman R, Cornel C, de Ziegler D, Taieb J, Spitz IM, Bouchard P.
    Hum Reprod; 1992 Aug; 7(7):930-3. PubMed ID: 1430131
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An analysis of the LH profile in relation to ovarian stimulation regimes and embryo transfer rates in an in vitro fertilisation programme.
    Umapathysivam K, Jones WR, Meffin E.
    Clin Reprod Fertil; 1986 Jun; 4(3):227-32. PubMed ID: 3091237
    [Abstract] [Full Text] [Related]

  • 11. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization.
    Gonen Y, Balakier H, Powell W, Casper RF.
    J Clin Endocrinol Metab; 1990 Oct; 71(4):918-22. PubMed ID: 2119392
    [Abstract] [Full Text] [Related]

  • 12. In vitro fertilization: diurnal and seasonal variation in luteinizing hormone surge onset and pregnancy rates.
    Casper RF, Erskine HJ, Armstrong DT, Brown SE, Daniel SA, Graves GR, Yuzpe AA.
    Fertil Steril; 1988 Apr; 49(4):644-8. PubMed ID: 3127247
    [Abstract] [Full Text] [Related]

  • 13. The efficacy of short-term gonadotrophin-releasing hormone agonists versus human chorionic gonadotrophin to enable oocyte release in gonadotrophin stimulated cycles.
    Check JH, Nazari A, Barnea ER, Weiss W, Vetter BH.
    Hum Reprod; 1993 Apr; 8(4):568-71. PubMed ID: 8501187
    [Abstract] [Full Text] [Related]

  • 14. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC.
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [Abstract] [Full Text] [Related]

  • 15. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.
    Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, Krebs D, Klingmüller D.
    Hum Reprod; 1994 May; 9(5):788-91. PubMed ID: 7929723
    [Abstract] [Full Text] [Related]

  • 16. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix.
    Tavaniotou A, Albano C, Smitz J, Devroey P.
    Hum Reprod; 2001 Apr; 16(4):663-7. PubMed ID: 11278214
    [Abstract] [Full Text] [Related]

  • 17. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE, Beall SA, Cox JM, Richter KS, DeCherney AH, Levy MJ.
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [Abstract] [Full Text] [Related]

  • 18. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L, Hall JE, Potau N, Carrascosa A, Prat N, Taylor AE.
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
    [Abstract] [Full Text] [Related]

  • 19. Relative bioactivity of endogenous luteinizing hormone during superovulation therapy for in vitro fertilization in normal-cycling women.
    Abuzeid MI, Hodges JK, Harlow CR, Hull MG.
    J Assist Reprod Genet; 1996 Sep; 13(8):629-34. PubMed ID: 8897122
    [Abstract] [Full Text] [Related]

  • 20. The efficacy of a combination administration of gonadotropin-releasing hormone agonist and gonadotropins for controlled ovarian hyperstimulation in IVF program.
    Chang YS, Kim SH, Shin CJ, Kim JG, Moon SY, Lee JY.
    Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):337-45. PubMed ID: 2129188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.